Related Experiment Video
Updated: Dec 2, 2025
08:59
A Model for Perineural Invasion in Head and Neck Squamous Cell Carcinoma
Published on: January 5, 2017
11.1K
Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma
Yingying Wang1, Yu Xu1,2, Qingquan Hua1
1Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China.
Biomed Research International
|November 2, 2020
Summary
This study developed a novel immune signature model to predict head and neck squamous cell carcinoma (HNSCC) patient prognosis. The model identifies key immune genes for improved treatment strategies.
Area of Science:
- Oncology
- Immunology
- Bioinformatics
Background:
- Understanding tumor immune characteristics and prognostic immune signals aids cancer patient management.
- Systematic analysis of immune signatures in head and neck squamous cell carcinoma (HNSCC) is currently limited.
Purpose of the Study:
- To decipher immune characteristics in HNSCC.
- To identify immune signals related to prognostic factors for HNSCC patients.
- To develop a predictive prognosis model for HNSCC.
Main Methods:
- Extracted 718 immune-related genes from RNA sequencing data of 519 HNSCC patients (TCGA database).
- Performed survival analysis and integrated bioinformatics analyses.
- Developed a predictive prognosis model using identified prognostic factors.
Main Results:
- Identified 178 survival-associated genes involved in immune cell activation and migration (P < 0.05).
- Discovered 35 independent prognostic factors using multivariate regression analysis (P < 0.01).
- The final prognostic model demonstrated high predictive efficiency (AUC = 0.963), with CD3E, CD40LG, TNFRSF4, CD3G, CD5, ITGA2B, ABCB1, and TNFRSF13b as key factors.
Conclusions:
- The developed prognostic model effectively predicts HNSCC patient outcomes based on immune signatures.
- The study provides novel predictive biomarkers for HNSCC.
- Identified potential therapeutic targets for HNSCC treatment.
